Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Go back to Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy| PROTHENA CORP (NASDAQ: PRTA) | Delayed: 9.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.15 | 52 Week High | $76.42 | |||
| Open | $9.15 | 52 Week Low | $28.20 | |||
| Day High | $9.15 | P/E | N/A | |||
| Day Low | $9.15 | EPS | $-2.84 | |||
| Volume | 17 | |||||
